MX2021011727A - Composiciones y metodos para tratar enfermedades oculares. - Google Patents
Composiciones y metodos para tratar enfermedades oculares.Info
- Publication number
- MX2021011727A MX2021011727A MX2021011727A MX2021011727A MX2021011727A MX 2021011727 A MX2021011727 A MX 2021011727A MX 2021011727 A MX2021011727 A MX 2021011727A MX 2021011727 A MX2021011727 A MX 2021011727A MX 2021011727 A MX2021011727 A MX 2021011727A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- ocular
- eye diseases
- various aspects
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title 1
- 238000002347 injection Methods 0.000 abstract 3
- 239000007924 injection Substances 0.000 abstract 3
- 208000022873 Ocular disease Diseases 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000003592 biomimetic effect Effects 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824017P | 2019-03-26 | 2019-03-26 | |
| PCT/US2020/024972 WO2020198481A1 (en) | 2019-03-26 | 2020-03-26 | Compositions and methods for treating ocular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011727A true MX2021011727A (es) | 2022-01-24 |
Family
ID=72609544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011727A MX2021011727A (es) | 2019-03-26 | 2020-03-26 | Composiciones y metodos para tratar enfermedades oculares. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12540171B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3946418A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7650074B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210146352A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113710264A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020248438A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134816A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202192607A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286625A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011727A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020198481A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202107235B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2015781A4 (en) * | 2005-09-12 | 2009-12-23 | Univ Johns Hopkins | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF |
| EP2649095B1 (en) * | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| JP6470740B2 (ja) * | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
| CN108883150A (zh) | 2015-11-19 | 2018-11-23 | 阿斯克雷佩西治疗公司 | 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂 |
| MX2019003895A (es) * | 2016-10-04 | 2019-10-07 | Asclepix Therapeutics Inc | Compuestos y metodos para activar la señalizacion tie2. |
| US20200179285A1 (en) * | 2017-05-08 | 2020-06-11 | The Johns Hopkins University | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
| EP3661536A4 (en) * | 2017-08-03 | 2021-07-21 | Asclepix Therapeutics, Inc. | PROCESS FOR IDENTIFICATION AND MANUFACTURING OF PHARMACEUTICAL INGREDIENTS FOR ACTIVATING A TIE2 RECEPTOR |
-
2020
- 2020-03-26 CN CN202080030026.4A patent/CN113710264A/zh active Pending
- 2020-03-26 KR KR1020217034683A patent/KR20210146352A/ko active Pending
- 2020-03-26 EP EP20776493.7A patent/EP3946418A4/en active Pending
- 2020-03-26 US US17/442,682 patent/US12540171B2/en active Active
- 2020-03-26 WO PCT/US2020/024972 patent/WO2020198481A1/en not_active Ceased
- 2020-03-26 AU AU2020248438A patent/AU2020248438A1/en active Pending
- 2020-03-26 JP JP2021557369A patent/JP7650074B2/ja active Active
- 2020-03-26 EA EA202192607A patent/EA202192607A1/ru unknown
- 2020-03-26 MX MX2021011727A patent/MX2021011727A/es unknown
- 2020-03-26 CA CA3134816A patent/CA3134816A1/en active Pending
-
2021
- 2021-09-23 IL IL286625A patent/IL286625A/en unknown
- 2021-09-27 ZA ZA2021/07235A patent/ZA202107235B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210146352A (ko) | 2021-12-03 |
| AU2020248438A1 (en) | 2021-10-28 |
| ZA202107235B (en) | 2023-10-25 |
| WO2020198481A1 (en) | 2020-10-01 |
| CA3134816A1 (en) | 2020-10-01 |
| EP3946418A4 (en) | 2023-02-22 |
| US12540171B2 (en) | 2026-02-03 |
| JP7650074B2 (ja) | 2025-03-24 |
| EA202192607A1 (ru) | 2022-03-03 |
| US20230054032A1 (en) | 2023-02-23 |
| CN113710264A (zh) | 2021-11-26 |
| IL286625A (en) | 2021-12-01 |
| JP2022527276A (ja) | 2022-06-01 |
| EP3946418A1 (en) | 2022-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011727A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| PH12021551792A1 (en) | Bi-ligand drug conjugate and use thereof | |
| EA201000787A1 (ru) | Антигенсвязывающие белки | |
| JP2017515811A5 (cg-RX-API-DMAC7.html) | ||
| MX383971B (es) | Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| AR045943A1 (es) | Formulaciones de acetonido de triamcinolona y acetato de anecortave para inyeccion | |
| CL2022000786A1 (es) | Metodos de tratamiento para modificar la hemodinamica | |
| JP2018504984A5 (cg-RX-API-DMAC7.html) | ||
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MX2021005077A (es) | Peptidos y composiciones farmaceuticas para tratar enfermedades oculares. | |
| RU2006142861A (ru) | Применение вязкоупругой композиции по новому назначению | |
| MX2022007911A (es) | Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7. | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| RU2017137763A (ru) | Депо-составы для инъекций | |
| MX2021014682A (es) | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. | |
| BR112022004535A2 (pt) | Formulações de entrega de fármaco | |
| EP4489746A4 (en) | Extended-release pharmaceutical compositions for the treatment of eye conditions | |
| EP4395706C0 (en) | AN INJECTOR KIT INTENDED FOR THE IMPLANTATION OF CORNEAL GRAFTS | |
| NZ622403A (en) | Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method | |
| AR108681A1 (es) | Proteínas de fusión para oftalmología con retención ocular aumentada | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases | |
| RU2012127869A (ru) | Устойчивые водные композиции пролекарств агонистов простагладина и способы их применения | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| TW200719893A (en) | Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery |